Showing 7391-7400 of 10047 results for "".
- ASDS: Dermatologists Remain the Primary Influencer for Patients’ Cosmetic Procedures, Skin Care Decisionshttps://practicaldermatology.com/news/asds-dermatologists-remain-the-primary-influencer-for-patients-cosmetic-procedures-skin-care-decisions/2462022/Board certified dermatologists hold the most sway when it comes to choosing a provider, cosmetic procedure, or skin care product, according to the
- Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-initiates-clinical-proof-of-concept-study-of-ep262/2462020/The first patient has been dosed in Escient Pharmaceuticals CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262, a first-in-class oral MRGPRX2 antagonist for chronic inducible urticaria. By blocking activation of MRGPRX2 and degranulation of mast cells,
- Study: AD Ups Risk for IBDhttps://practicaldermatology.com/news/study-ad-ups-risk-for-ibd/2462009/Adults with atopic dermatitis (AD) have a 34% increased risk of developing new-onset inflammatory bowel disease (IBD) compared with individuals who do not have the skin condition, and children have a 44% increased risk, according to a new study from the P
- ‘SUNucate’ Laws Do Increase Interest in Sun Protection, Youth Sunscreen Usehttps://practicaldermatology.com/news/sunucate-laws-do-increase-interest-in-sun-protection-youth-sunscreen-use/2461998/States that enacted SUNUCATE laws permitting children to carry and apply sunscreen at school experienced an increased interest in sun protection and a higher rate of sunscreen use among adolescents, according to new research by a University of Massachusetts Amherst resource economist.
- Tarsus Rolls Out XDEMVY for Demodex Blepharitishttps://practicaldermatology.com/news/tarsus-rolls-out-xdemvy-for-demodex-blepharitis/2461985/Tarsus Pharmaceuticals, Inc. is rolling out XDEMVY, the First and Only US Food and Drug Administration-approved treatment for Demodex blepharitis. XDEMVY is now available at pharmacies nationwide for prescription. Bobak Azamian, MD, PhD, Chief Executive Officer, and Chairman, ran
- Is PIILIF the Precursor to Scarring Alopecias?https://practicaldermatology.com/news/is-piilif-the-precursor-for-scarring-alopecias/2461978/A single root condition called PIILIF (perifollicular infundibulo-isthmic lymphocytic infiltrates and fibrosis) may be a precursor for acne keloidalis nuchae (AKN) and primary cicatricial alopecias, according to a study in
- Houston Dermatologist Rolls Out New Class of Topical Pain Relievershttps://practicaldermatology.com/news/houston-dermatologist-rolls-out-new-class-of-topical-pain-relievers/2461974/Milton D. Moore, MD, a dermatologist and founder & CEO of Moore Unique Skin Care, LLC and
- Experts to Develop Human Skin Cell Atlashttps://practicaldermatology.com/news/experts-to-develop-human-skin-cell-atlas/2461944/A grassroots movement to establish a Human Skin Cell Atlas is underway, according to a review in the Journal of Investigative Dermatology. To perform its numerous functions and to maintain pr
- La Roche-Posay Is the Official Sunscreen of the US Open for the Second Yearhttps://practicaldermatology.com/news/la-roche-posay-is-the-official-sunscreen-of-the-us-open-for-the-second-year/2461941/La Roche-Posay is continuing its partnership as the exclusive Official Sunscreen Partner of the US Open for the second year in a row. At the 2022 US Open, La Roche-Posay provided access to board-certified dermatologists to educate on sun safety and distributed 300,000 free sunscree
- Inmagene's OX40 mAb Enters POC Study in ADhttps://practicaldermatology.com/news/inmagenes-ox40-mab-enters-poc-study-in-ad/2461934/The first patient has been dosed in a global multicenter proof-of-concept (POC) study of Inmagene Biopharmaceuticals’ IMG-007 in adults with moderate-to-severe atopic dermatitis (AD). The objective of the study is to assess the safety, pharmacokinetics, and efficacy of